...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Dermatologic surgery >Melanoma Outcomes in Transplant Recipients With Pretransplant Melanoma
【24h】

Melanoma Outcomes in Transplant Recipients With Pretransplant Melanoma

机译：移植前黑素瘤患者的黑色素瘤结果。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUNDThere are limited data on outcomes in transplant recipients with a history of pretransplant melanoma.OBJECTIVETo determine whether pretransplant melanoma is associated with differences in survival or posttransplant melanoma risk.MATERIALS AND METHODSWe evaluated the outcomes of 185,039 US transplant recipients from the Transplant Cancer Match Study. We also evaluated the impact of transplantation on 141,441 patients with melanoma identified in cancer registries.RESULTSThere were 336 transplant recipients (0.18%) with pretransplant melanoma; they had increased risk of melanoma-specific mortality (hazard ratio [HR], 27; 95% confidence interval [CI], 11-64, p < .0001), overall mortality (HR, 1.3; 95% CI, 1.0-1.5, p = .02), and incident melanoma (HR, 5.4; 95% CI, 2.9-9.8, p < .0001) after transplant, compared with recipients without pretransplant melanoma. The 10-year absolute risk difference was 2.97% for melanoma-specific mortality, 3.68% for incident melanoma, and 14.32% for overall mortality. Among the 141,441 patients with melanoma in the general population, 68 (0.05%) subsequently received a transplant. Transplantation increased melanoma-specific mortality, but not significantly (HR, 1.7; 95% CI, 0.61-4.5, p = .32).CONCLUSIONPretransplant melanoma is associated with increased melanoma-specific mortality, overall mortality, and incident melanoma after transplant. Nonetheless, the rarity of melanoma-related events supports the current practice for listing transplant candidates with a history of melanoma.
机译：背景移植前黑色素瘤病史的移植受者的结局数据有限。目的是确定移植前黑色素瘤是否与生存率差异或移植后黑素瘤风险有关。材料与方法我们评估了185,039名来自移植癌匹配研究的美国移植受者的结果。我们还评估了移植对在癌症登记处确定的141,441例黑素瘤患者的影响。结果336例接受移植的黑素瘤患者（0.18％）接受了移植。他们的黑素瘤特异性死亡风险（危险比[HR]为27; 95％置信区间[CI]为11-64，p <.0001），总死亡率（HR为1.3; 95％CI为1.0-1.5）增加了，p = .02）和移植后发生的黑色素瘤（HR，5.4; 95％CI，2.9-9.8，p <.0001），与未移植前黑色素瘤的接受者相比。对于黑色素瘤特定死亡率，十年期绝对风险差异为2.97％，黑色素瘤突发事件为3.68％，总死亡率为14.32％。在普通人群的141,441名黑色素瘤患者中，有68名（0.05％）随后接受了移植。移植增加了黑色素瘤特异性死亡率，但没有显着增加（HR，1.7; 95％CI，0.61-4.5，p = 0.32）。尽管如此，与黑色素瘤相关事件的罕见性仍支持当前列出具有黑色素瘤病史的移植候选者的实践。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号